Who mentions $CAPR most on Surfaced?

@adamfeuerstein (Adam Feuerstein ✡️) mentions $CAPR most — 22 mentions in the past 12 months.

When was $CAPR first mentioned on Surfaced?

The earliest tracked mention of $CAPR in the Surfaced archive was on Aug 26, 2025.

How many voices track $CAPR?

2 FinTwit voices have mentioned $CAPR 21 times in the past 12 months.

What kind of voices mention $CAPR most?

$CAPR is mentioned most by Biotech voices on Surfaced.

Last 12mo stats

mentions

voices

$CAPR

Capricor Therapeutics

$CAPR

Capricor Therapeutics

Past 12mo:21mentions2voices

All voices8 calls since Sep 2025show all

Loading price chart…

About this stock

Over the past 12 months, $CAPR generated 21 mentions from 2 distinct FinTwit voices, with the discussion concentrated heavily among biotech-focused accounts. Adam Feuerstein (@adamfeuerstein) dominated the conversation with 22 mentions, while Wayne Liang (@wliang) contributed 1 mention. The first mention appeared on August 26, 2025, and the most recent activity occurred on July 7, 2026.

The most recent discussion centered on Capricor's deramiocel cell therapy for Duchenne muscular dystrophy, with an FDA advisory committee meeting scheduled for July 29, 2026. Adam Feuerstein reported on potential FDA concerns regarding possible inadvertent unblinding to study results prior to submitting a revised statistical analysis plan, citing comments from Capricor CEO Linda Marban who stated the company was not unblinded and that changes were made with FDA blessing.

AI-generated from tracked posts · updated Aug 24, 2026

Related stocks

$IBRXImmunitybio

$HIMSHims & Hers Health

Recent calls

8 calls

@adamfeuersteinJul 7, 2026 · 1:43 PM

The FDA adcomm for $REPL RP1 has been scheduled for July 30, according to a notice in the Federal Register. That's one day after the $CAPR deramiocel adcomm on July 29.

Open on X

@adamfeuersteinJul 6, 2026 · 1:03 PM

-- FDA adcomms are back. On July 29, an expert panel will evaluate deramiocel, $CAPR cell therapy for Duchenne muscular dystrophy. Historically, the FDA convenes a panel of outside experts to seek advice on unresolved issues or concerns that crop up during a drug review. This helps explain why Capricor shares are down. I spoke to Capricor CEO Linda Marban... “The FDA hasn’t asked us anything that has made me think there are flies in the ointment or there’s something that they are really picking on,” Capricor CEO Linda Marban told me. But... One issue the FDA may bring to the advisory panel, Marban speculated, based on some of these information requests, is the possibility that Capricor may have been inadvertently unblinded to the study results prior to submitting a revised statistical analysis plan to the agency. Recall, Capricor $CAPR changed the method used to analyze the muscle-performance primary endpoint -- relative change from mean change -- and also revised the statistical analysis plan. Marban said the company was not unblinded and changes were made with the blessing of the FDA. “We provided all of that information to the agency, but I think that’s probably one of the issues they want to flesh out” at the advisory panel meeting, she said.

Open on X

@adamfeuersteinJun 26, 2026 · 12:56 PM

FDA advisory committee meetings are back. $CAPR deramiocel will be reviewed on July 29, per a notice in the Federal Register. $REPL RP1 will be reviewed in "late July," per the company this morning.

Open on X

@adamfeuersteinMay 7, 2026 · 9:10 PM

$CAPR is suing NS Pharma, its deramiocel commercial partner. Capricor alleges NS Pharma is not doing enough to prepare for commercial launch + some pricing mishegas. 8K https://t.co/7iFyLRhKsq

Open on X

@adamfeuersteinMar 10, 2026 · 1:47 PM

$CAPR resubmission of the deramiocel application accepted by the FDA. New decision date: Aug. 22. https://t.co/mWSyyXg8di

Open on X

@adamfeuersteinDec 3, 2025 · 1:00 PM

On $CAPR, the primary endpoint was not changed. Those alleging otherwise are incorrect. The mean change on the PUL 2.0 endpoint was 1.2 points favoring deramiocel over placebo. From CEO Linda Marban: "Capricor’s external statistical vendor followed the pre-specified statistical analysis for the protocol specified primary endpoint of the HOPE-3 trial. This was detailed in a statistical analysis plan that was finalized prior to unblinding."

Open on X

@adamfeuersteinNov 10, 2025 · 9:11 PM

$CAPR no HOPE-3 data tonight with earnings release. Study results "expected in the coming weeks."

Open on X

@adamfeuersteinSep 25, 2025 · 11:20 AM

$CAPR regulatory update after FDA meeting: HOPE-3 study primary endpoint unchanged. https://t.co/26IzYAiMM1

Open on X

About this stock

Related stocks

Frequently asked